Chugai Q1 FY2026 Results
- Core revenue ¥321.7B (+11.5%), core operating profit ¥163.3B (+17.1%), core net income ¥118.6B (+19.6%).
- Product updates: Elevidys launched in Japan for Duchenne muscular dystrophy; Lunsumio plus Polivy approved for relapsed/refractory large B‑cell lymphoma.
- Foundayo (orforglipron), an oral GLP‑1 receptor agonist out‑licensed to Eli Lilly, received U.S. approval for obesity and is under review in 40+ countries including Japan and the EU.
- R&D: NXT007 showed favorable tolerability when switching directly from Hemlibra in Phase I/II Part C; Enspryng Phase III MOGAD results were presented and a regulatory filing is planned within the year.
Financial results
Core revenue ¥321.7 billion (+11.5%), core operating profit ¥163.3 billion (+17.1%) and core net income ¥118.6 billion (+19.6%); domestic sales ¥111.4B (+8.2%), overseas sales ¥180.1B (+14.9%), other revenue ¥30.2B (+5.2%).
Product approvals and launches
Launched Elevidys in Japan as the first regenerative medical product for Duchenne muscular dystrophy; Lunsumio combined with Polivy approved for relapsed or refractory large B‑cell lymphoma; Foundayo (orforglipron), out‑licensed to Eli Lilly, received U.S. approval for obesity and is under regulatory review in more than 40 countries including Japan and the EU.
R&D and pipeline progress
NXT007 showed favorable tolerability in Part C of the Phase I/II NXTAGE study after direct switching from Hemlibra without washout; Enspryng Phase III results in MOGAD were presented and a regulatory filing is being prepared within the year; Chugai‑originated projects advanced across early and late stages, on track to reach the company’s highest number of planned applications.
Source: Chugai Pharmaceutical